

# SARS-CoV-2 (2019-nCoV) Spike RBD Mouse mAb

SARS-CoV-2 (2019-nCoV) Spike RBD Mouse mAb Catalog # AP94782

### **Product Information**

Application WB
Host Rabbit
Clonality Monoclonal
Calculated MW 140 KDa
Physical State Liquid

Immunogen Recombinant SARS-CoV-2 Spike S1 Protein

Epitope Specificity 14-685/1213

**Purity** affinity purified by Protein A

**Buffer** 0.01M PBS (pH7.4).

**SUBCELLULAR LOCATION** Virion membrane; Single-pass type I membrane protein; Host endoplasmic

reticulum-Golgi intermediate compartment membrane; Single-pass type I membrane protein; Host cell membrane; Single-pass type I membrane protein; Note: Accumulates in the endoplasmic reticulum-Golgi intermediate compartment, where it participates in virus particle assembly. Colocalizes with S in the host endoplasmic reticulum-Golgi intermediate compartment. Some S oligomers are transported to the host plasma membrane, where they

may mediate cell-cell fusion.

**SUBUNIT** Spike glycoprotein: Homotrimer; each monomer consists of a S1 and a S2

subunit (PubMed:32155444, PubMed:32075877). The resulting peplomers protrude from the virus surface as spikes (By similarity). Interacts with the accessory proteins 3a and 7a.Spike protein S1: Binds to human ACE2. The cytoplasmic Cys-rich domain is palmitoylated. Spike glycoprotein is

Post-translational modifications

digested within host endosomes. Specific enzymatic cleavages in vivo yield mature proteins. The precurssor is processed into S1 and S2 by host cell furin

or another cellular protease to yield the mature S1 and S2 proteins

(PubMed:32155444). Additionally, a second cleavage leads to the release of a fusion peptide after viral attachment to host cell receptor (By similarity). The presence of a furin polybasic cleavage site sets SARS-CoV-2 S apart from SARS-CoV S that possesses a monobasic S1/S2 cleavage site processed upon entry of target cells (PubMed:32155444). Highly decorated by heterogeneous

N-linked glycans protruding from the trimer surface.

**Important Note** This product as supplied is intended for research use only, not for use in

human, therapeutic or diagnostic applications.

**Background Descriptions** The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end

the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in

the context of a soluble S ectodomain construct.

## **Additional Information**

#### Target/Specificity

The cytoplasmic Cys-rich domain is palmitoylated. Spike glycoprotein is digested within host endosomes. Specific enzymatic cleavages in vivo yield mature proteins. The precurssor is processed into S1 and S2 by host cell furin or another cellular protease to yield the mature S1 and S2 proteins (PubMed:32155444). Additionally, a second cleavage leads to the release of a fusion peptide after viral attachment to host cell receptor (By similarity). The presence of a furin polybasic cleavage site sets SARS-CoV-2 S apart from SARS-CoV S that possesses a monobasic S1/S2 cleavage site processed upon entry of target cells (PubMed:32155444). Highly decorated by heterogeneous N-linked glycans protruding from the trimer surface.

**Dilution** WB=1:500-2000

Format 0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce

**Storage** Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When


reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody

is stable for at least two weeks at 2-4 °C.


# **Background**

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

## **Images**



Sample: Lane 1: SARS-CoV-2 Spike RBD Protein (His-Avi,HEK293) at 500ng Lane 2: SARS-CoV-2 S1 Protein (His-Avi,HEK293) at 500ng Primary: Mouse Anti-SARS-CoV-2 Spike RBD Protein Antibody at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution Predicted band size: 27/78kD Observed band size: kD



Sample: Lane 1: SARS-CoV-2 Spike RBD Protein(WT) at 500ng Lane 2: SARS-CoV-2 Spike S1 Protein(E484Q, L452R, D614G,P681R) at 500ng Lane 3: SARS-CoV-2 Spike S1 Protein (D80A, D215G, del241/243, K417N, E484K, N501Y, D614G) at 500ng Lane 4: SARS-CoV-2 Spike S1 Protein (L18F, T20N, P26S, D138Y, R190S,K417T,E484K,N501Y,D614G,H655Y) at 500ng Lane 5: SARS-CoV-2 Spike S1 Protein (WT) at 500ng Primary: Anti- SARS-CoV-2 Spike S1 Protein at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution Predicted band size: 27kDa /77.2 kDa Observed band size: 35kDa/114 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.